Last updated: May 29, 2026
Bupivacaine Hydrochloride and Epinephrine: Key Pharmaceutical Suppliers, API/Intermediate Sources, and Contract Manufacturing Options
Bupivacaine hydrochloride plus epinephrine is supplied through a mix of brand and generic manufacturers, with upstream API and salt epinephrine sourcing typically handled by specialized API companies and salt/biomolecule excipient supply chains. In the US, demand is primarily met via injectable generics and label holders listed on the FDA Orange Book for locally administered anesthetic combinations.
No complete, verified supplier roster (by firm, product strength, NDC labeler, site, and component split) can be produced from the information provided in the prompt alone.
Which companies supply bupivacaine hydrochloride and epinephrine injectable drugs in the US?
Featured market-facing suppliers for the combination are generally the firms that hold FDA-labeled products (NDC labelers) for bupivacaine HCl with epinephrine. These suppliers appear as manufacturers of record on product labeling and Orange Book entries for the relevant strengths and dosage forms.
What dosage forms and strengths drive supplier coverage?
The supplier set is typically segmented by:
- Injection strength (commonly expressed as mg/mL bupivacaine HCl with epinephrine concentration, depending on the product)
- Container type (single-dose vs multi-dose vials/ampules)
- Packaging (carton configuration, NDC variants)
Who makes the bupivacaine hydrochloride active pharmaceutical ingredient (API)?
API suppliers for bupivacaine hydrochloride generally operate through:
- Sale of bupivacaine HCl API to generic injectables makers
- Contract manufacture of intermediate steps (chiral synthesis and salt formation)
- Batch release and quality documentation tied to DMF filings or supplier qualifications
How do API DMFs affect supplier selection?
Injectable manufacturers often qualify API sources through:
- DMF-backed supply chains (where available)
- Site qualification and stability programs
- OOS/OOT handling agreements tied to sterilization and container closure requirements downstream
Who supplies epinephrine (API) for injectable anesthetic combinations?
Epinephrine suppliers typically include specialized API producers that handle:
- Chemical synthesis and purification of epinephrine base
- Salt form control (where applicable) and conversion handling to match the formulation specification
- Sterility-adjacent packaging logistics for final injectable manufacturing
Does epinephrine sourcing constrain manufacturing capacity?
Supplier risk tends to concentrate around:
- Lot-to-lot potency and impurity profile control
- Stability under light/oxygen exposure, which can tighten sourcing tolerances
- Supply continuity for critical starting materials
What contract development and manufacturing organizations (CDMOs) support bupivacaine-epinephrine injectables?
Final dose manufacturing (sterile injectable production) usually involves:
- Aseptic filling lines and sterilized drug product manufacturing
- QA release testing for potency, pH, and specified impurities
- Container closure integrity testing aligned to epinephrine stability needs
Which CDMO capabilities matter most?
For bupivacaine HCl with epinephrine, supplier selection typically weighs:
- Aseptic processing and sterility assurance level (SAL) capability
- Ability to manage photosensitivity and oxidative degradation
- Experience with local anesthetic formulations and regulatory documentation
How does supplier structure differ between brand and generic bupivacaine-epinephrine products?
Brand supply chains often include direct manufacturing or preferred CMOs for sterile injectables, while generic supply chains more often use:
- API and excipient supply from multiple qualified vendors
- Contract fill-finish and sterilization execution by third parties
What drives switching between suppliers?
Common triggers include:
- Regulatory lifecycle events (supplement submissions, labeling changes)
- Batch failures or OOS investigations
- Cost down initiatives tied to contract tendering and yield improvements
What patents, exclusivity, and regulatory status affect who can supply bupivacaine-epinephrine products?
Supplier entry is governed by:
- Orange Book listed patents and exclusivity attached to specific NDCs/filings
- FDA approval pathway (ANDA for generics, 505(b)(2) pathways in limited cases)
What is the Orange Book status for bupivacaine HCl with epinephrine?
This requires Orange Book lookup by exact strength, dosage form, and dosage unit.
Which generic launch scenarios are most relevant for bupivacaine hydrochloride and epinephrine injectables?
For injectable anesthetic combinations, new entry scenarios typically include:
- Full generic approvals for products with expired exclusivity and cleared patent barriers
- Potential Paragraph IV challenges when listed patents remain in force for a specific NDC
How many patent-protected product variants exist?
This varies by strength and NDC; it cannot be quantified without Orange Book-driven enumeration for the relevant combination.
Key Takeaways
- Supplier coverage for bupivacaine hydrochloride plus epinephrine is driven by sterile injectable manufacturing and API qualification for bupivacaine HCl and epinephrine.
- Upstream supply often runs through API producers and qualified intermediate suppliers, while downstream supply is dominated by companies holding injectable NDC labelers or fill-finish partners.
- A verified, firm-by-firm supplier list (API suppliers, epinephrine suppliers, sterile fill-finish/CDMOs, and US labelers/NDCs) cannot be generated from the prompt alone without Orange Book and labeling identifiers for the specific strengths and dosage forms.
FAQs
- Which API suppliers produce bupivacaine hydrochloride suitable for injectable generic manufacturing?
- How do epinephrine stability and impurity profiles change sourcing requirements for sterile injectables?
- What sterile manufacturing and aseptic filling capabilities do CDMOs need for bupivacaine-epinephrine formulations?
- What FDA Orange Book listings typically govern generic entry for bupivacaine hydrochloride plus epinephrine by NDC strength?
- What risks drive supply continuity issues for epinephrine-containing local anesthetic combinations?
References
No sources are cited because no Orange Book entries, NDCs, patent listings, labeling records, DMFs, or manufacturer sites were provided in the prompt.
